Table 1.
Test | Advantages | Disadvantages |
---|---|---|
ACT | • Inexpensive • POC • Whole blood test |
• Measures end point of the clotting cascade, but does not solely tell you about UFH effect |
aPTT | • Accepted means of titrating anticoagulation therapy for both UFH and DTI • POC now available |
• High degree of intra- and interpatient variability especially in infants • Less reliable in critical illness |
Anti-Xa | • Specific measure of UFH effect based on the ability of UFH to catalyze AT’s inhibition of factor Xa • Better association with UFH dose |
• Elevated plasma-free hemoglobin and hyperbilirubinemia will underestimate UFH activity by anti-Xa |
TEG/ROTEM | • POC • Whole blood test • Provides information about both clot strength and fibrinolysis |
• Limited availability |
UFH, unfractionated heparin; POC, point-of-care; AT, antithrombin; DTI, direct thrombin inhibitor; TEG, thromboelastography; ROTEM, rotational thromboelastometry.